1) Results of the liraglutide effect and action in diabetes - evaluation of
cardiovascular outcome results (LEADER) trial. Scientific Sessions at the 52nd Annual
Meeting of the European Association for the Study of Diabetes (EASD) 2016. 15
September 2016.
2) Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes
in type 2 diabetes. New England Journal of Medicine 2016; 375:311-322.
3) Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes
in type 2 diabetes. Supplementary Information. New England Journal of Medicine 2016;
375:311-322.
4) Gallagher H, Suckling RJ. Diabetic nephropathy: where are we on the journey from
pathophysiology to treatment? Diabetes, Obesity and Metabolism 2016; 18:641-647.
5) EMA. Victoza(R) EU summary of product characteristics. Available at:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_...
. Last accessed: September 2016.
6) Internal Calculations based on IMS Midas Quantum data. March 2016.
7) FDA. Victoza(R) US prescribing information. April 2016. Available at:
http://www.novo-pi.com/victoza.pdf. Last accessed: August 2016.
Andalucía
Aragón
Cantabria
Castilla-La Mancha
Castilla y León
Catalunya
Extremadura
Galicia
Islas Canarias
Islas Baleares
Madrid
País Vasco
La Rioja
C. Valenciana
Navarra
Asturias
Murcia
Ceuta y Melilla
